A phase II trial of rituximab as adjuvant to intensive sequential chemotherapy in patients under 60 years with untreated poor-prognosis diffuse large B-cell lymphoma-Reference-Cited by-同舟云学术

A phase II trial of rituximab as adjuvant to intensive sequential chemotherapy in patients under 60 years with untreated poor-prognosis diffuse large B-cell lymphoma

Published:2006-06-12 Issue:3 Volume:38 Page:217-222
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Coso D,Sebban C,Boulat O,Biron P,Rey J,Aurran T,Chabannon C,Xerri L,Chetaille B,Esterni B,Ivanov V,Stoppa A M,Schiano de Collela J M,Gastaut J A,Maraninchi D,Bouabdallah R

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/1705414.pdf

Reference20 articles.

1. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J et al. The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting – Airlie House, Virginia, November, 1997. Hematol J 2000; 1: 53–66.

2. The international non-Hodgkin's lymphoma prognostic factors project: a predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987–994.

3. Haioun C, Lepage E, Gisselbrecht C, Bastion Y, Coiffier B, Brice P et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non Hodgkin's lymphoma: Updated results of the prospective study LNH87-2. J Clin Oncol 1997; 15: 1131–1137.

4. Santini G, Salvagno L, Leoni P, Chisesi T, De Souza C, Sertoli MR et al. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non Hodgkin's lymphoma: Results of a prospective randomized trial by the non Hodgkin's lymphoma cooperative study group. J Clin Oncol 1998; 16: 2796–2802.

5. Haioun C, Lepage E, Gisselbrecht C, Thieblemont C, Simon D, Rose C et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol – A Groupe d'Etude des Lymphomes de l'Adulte Study. J Clin Oncol 2000; 18: 3025–3030.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of Correlation Between Early and Late Efficacy Endpoints to Identify Potential Surrogacy Relationships in Non-Hodgkin Lymphoma: a Literature-Based Meta-analysis of 108 Phase II and Phase III Studies;The AAPS Journal;2017-02-21

2. Characteristics and survival of BCR/ABL negative chronic myeloid leukemia: a retrospective analysis of the Surveillance, Epidemiology and End Results database;Therapeutic Advances in Hematology;2015-09-30

3. Risk of second primary malignancies and survival of adult patients with polycythemia vera: A United States population-based retrospective study;Leukemia & Lymphoma;2015-09

4. Mortality Patterns Among Recipients of Autologous Hematopoietic Stem Cell Transplantation for Lymphoma and Myeloma in the Past Three Decades;Clinical Lymphoma Myeloma and Leukemia;2015-07

5. Hematopoietic Stem Cell Transplantation for Non-Hodgkin Lymphoma;Hematology/Oncology Clinics of North America;2014-12